What Mepha Pharma does

Mepha Pharma is a Swiss pharmaceutical company headquartered in Basel, with operations traceable to 1949, and currently functioning as a subsidiary of Teva Pharmaceutical Industries Ltd., the Israeli global pharmaceutical company. The company offers approximately 330 products spanning four categories: generics, biosimilars, original branded medications, and over-the-counter (OTC) products. Its commercial footprint covers Switzerland and Liechtenstein.

Mepha serves a diversified customer base that includes physicians, retail pharmacies, hospital pharmacies, pharmaceutical wholesalers, and specialty customers. Distribution is executed through a direct field sales force combined with GDP-compliant delivery infrastructure offering two-business-day fulfillment. The company supplements its physical distribution with a set of digital tools aimed at healthcare professionals: a professional portal (Fachportal), a returns management tool (Retourentool), and a price reduction tool (Preissenkungstool).

As a Teva subsidiary, Mepha's business model relies on parent-level manufacturing scale and portfolio breadth to compete in the Swiss generics and biosimilars market, while running a Switzerland-specific commercial operation with dedicated Strategic Business Account Management (SBAM) for key accounts including Medbase and Galenica. Pricing follows standard Swiss pharmaceutical distribution conventions; revenue mechanics reflect wholesale and direct-to-pharmacy channel economics rather than subscription or platform pricing. Mepha maintains a routine regulatory maintenance cycle, with updated pharmacovigilance policy (June 2025), privacy policy (April 2025), and revised General Terms and Conditions (April 2024).

Name

Mepha Pharma

Legal name

Mepha Pharma AG

Website

https://mepha.ch

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Mepha Pharma is a Swiss pharmaceutical subsidiary of Teva offering approximately 330 generics, biosimilars, branded, and OTC products to physicians, pharmacies, and wholesalers across Switzerland and Liechtenstein.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Complex Generics (e.g., inhalation, transdermal, liposomal) (HLAIABAB), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Branded medications
• Over-the-counter drugs
• Pharmaceutical manufacturing

Headquarters

HQ city

Aesch

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Sale of generic drugs — the core business. Mepha offers approximately 330 products covering nearly all important therapeutic areas, providing cost-effective alternatives to originator medications for the Swiss healthcare system.
2. Biosimilars: Sale of biosimilar products — biopharmaceutical equivalents offering cost-effective alternatives to reference biologics, contributing to affordable healthcare delivery in Switzerland.
3. Original Branded Medications: Sale of innovative proprietary medications (Originalmedikamente) complementing the generic portfolio, offering treatment options in therapeutic areas where branded therapies are preferred or required.
4. Over-the-Counter (OTC) Products: Sale of non-prescription, freely available (frei erhältliche) OTC products directly to consumers through pharmacies, expanding access beyond prescription-only medicines.
5. Logistics and Handling Services: Logistics cost surcharges applied to all paid orders, handling fees for orders below CHF 250, and express delivery fees of CHF 25, as well as return processing fees of CHF 10.

Pricing tiers

Go-to-market motion1 record

Distribution channels9 records

Marketing channels5 records

Core offering

Mepha Pharma develops, manufactures, and markets approximately 330 pharmaceutical products in Switzerland, including generic medications, biosimilars, innovative original branded medications, and over-the-counter (OTC) products spanning nearly all important therapeutic areas. Products are sold to physicians, pharmacies, hospital pharmacies, wholesalers, and other professional healthcare buyers through a nationwide field sales force and digital professional portal.

Product overview

Mepha Pharma is a Swiss pharmaceutical company and part of the international Teva Group, operating since 1949. The company offers a broad portfolio of approximately 330 products spanning generics, biosimilars, innovative original medications, and OTC products covering nearly all important therapeutic areas. The product portfolio is supported by a digital specialist portal (Mepha/Teva Fachportal) that provides healthcare professionals with detailed product information, bioequivalence data, availability information, and online ordering. Additional digital service tools include a returns tool (Retourentool) for processing product returns and a price reduction tool (Preissenkungstool) for inventory value adjustments. Notable individual products include the autotest VIH® HIV self-test for consumer use.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic pharmaceuticals (Generika) Generic pharmaceutical products providing cost-effective treatment alternatives to originator medicines across nearly all important therapeutic areas in Switzerland. Sold to physicians, pharmacies, hospital pharmacies, and wholesalers as the core portfolio offering.
• Biosimilars Biosimilar pharmaceutical products offering cost-effective alternatives to reference biologic medicines for the Swiss healthcare system. Sold to physicians, pharmacies, and hospital pharmacies as part of Mepha's broad specialty portfolio.
• Original branded medications (Originalmedikamente) Innovative proprietary branded medications developed and marketed through Mepha/Teva, offering therapy options in therapeutic areas where branded treatments are preferred or required. Sold to physicians, pharmacies, and hospital pharmacies.
• Over-the-counter (OTC) products Non-prescription, freely available (frei erhältliche) pharmaceutical products sold through pharmacies to consumers for self-medication. Expands Mepha's offering beyond prescription-only medicines across a range of indications.
• autotest VIH® HIV self-test An anonymous self-test for determining HIV status that can be performed at home, distributed as part of Mepha's OTC and self-medication portfolio.

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• Teva Pharmaceutical Industries Ltd.coreStrategic or Co-development PartnerMepha is the Swiss subsidiary and local brand of Teva Pharmaceutical Industries Ltd., an international pharmaceutical group headquartered in Israel. Mepha Pharma AG and Teva Pharma AG are co-located at the same address in Basel and share operations, sales organizations, and systems. Mepha benefits from Teva's global resources, R&D capabilities, product portfolio, and corporate infrastructure, combining local Swiss expertise with global pharmaceutical capabilities. Teva's global structure provides Mepha with access to generics, biosimilars, and innovative medications.
• Swiss RX (Stiftung Refdata)coreTechnology or IntegrationSwiss RX is a service provided by Stiftung Refdata, Baarerstrasse 2, CH-6300 Zug, enabling professional verification for healthcare professionals accessing restricted pharmaceutical information on the Mepha website. Healthcare professionals can log in using their Swiss RX credentials without creating a separate Mepha account. Mepha receives professional qualification, name, email, and address data upon user consent for data transfer.
• DocCheck Medical Services GmbHcoreTechnology or IntegrationDocCheck is a medical professional verification service operated by DocCheck Medical Services GmbH, Vogelsanger Strasse 66, DE-50823 Köln. Healthcare professionals can log in to the Mepha website using their DocCheck credentials, enabling access to restricted pharmaceutical information without a separate Mepha account registration. Username and password verification occurs directly on DocCheck servers.
• MedbaseflagshipStrategic or Co-development PartnerMedbase is managed under the Strategic Business Account Management (SBAM) program. Mepha maintains a dedicated Strategic Business Account Manager for Medbase (Manuela Bollhalder), indicating a significant strategic partnership involving close collaboration, tailored strategies, and continuous development of services and cooperation.
• GalenicaflagshipStrategic or Co-development PartnerGalenica is managed under the Strategic Business Account Management (SBAM) program. Mepha maintains a dedicated Strategic Business Account Manager for Galenica (Olivier Maillat), indicating a significant strategic partnership with one of Switzerland's largest pharmacy and healthcare groups, involving close collaboration and tailored strategies.
• SmartIn Pharma AG ([email protected])minorChannel Partner/ Reseller/ DistributorSmartIn Pharma AG handles medical access and Art. 71 KVV physician requests for Mepha products, serving as a specialized contact point for market access inquiries related to Mepha's pharmaceutical portfolio.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Streuli Pharma AG: Streuli Pharma is a long-standing Swiss pharmaceutical manufacturer and distributor of generic and OTC products, serving Swiss pharmacies and healthcare professionals with a comparable generics-focused portfolio.
• Amedis AG: Amedis (part of Aevis Victoria) is a Swiss pharmaceutical company offering generic pharmaceuticals and healthcare products distributed through Swiss pharmacies, operating as a direct competitor to Mepha in the generics segment.
• Vifor Pharma (CSL Vifor): CSL Vifor is a Swiss specialty pharmaceutical company focused on iron deficiency, nephrology, and rare diseases, headquartered in St. Gallen. While more specialty-focused than Mepha, it is a comparable Swiss-headquartered pharma company selling to the same physician and pharmacy channels.
• Sandoz: Recently spun out from Novartis, Sandoz is the world's largest generics company and Mepha's primary direct competitor in the Swiss generics market, offering overlapping portfolios of generic pharmaceuticals, biosimilars, and distribution to pharmacies and hospitals in Switzerland.
• Spirig HealthCare AG: Spirig HealthCare is a Swiss pharmaceutical company with a portfolio spanning generics, OTC, and dermatology products, comparable to Mepha's mix of generics, biosimilars, original medications, and OTC offerings in the Swiss market.
• Helvepharm AG: Helvepharm is a Swiss pharmaceutical company specializing in generic and off-patent medicines distributed through Swiss pharmacies and physicians, directly competing with Mepha across therapeutic areas in the same Swiss market.

Regional players

• GEBRO Pharma AG: GEBRO Pharma is a Swiss-Austrian pharmaceutical company offering generic and specialty medicines primarily in Switzerland and Austria, comparable to Mepha in generics focus but with a different geographic footprint in the DACH region.
• Dr. A. & L. Schmidgall GmbH & Co KG: Schmidgall is an Austrian family-owned pharmaceutical manufacturer and distributor of generic and OTC products, comparable to Mepha in product mix but primarily serving Austria rather than Switzerland, making it a regional rather than direct peer.

Others

• Galenica AG: Galenica is one of Switzerland's largest pharmacy retail and wholesale groups, and is both a key SBAM customer of Mepha (with a dedicated Strategic Business Account Manager) and an adjacent player via its pharmaceutical distribution arm Galexis. It is an ecosystem participant and channel partner rather than a direct generics competitor.

Broad incumbents

• Bayer (Schweiz) AG: Bayer Schweiz operates as the Swiss arm of global pharma major Bayer, offering a broad portfolio including generics and consumer health products. It competes with Mepha in selected therapeutic areas and OTC, but operates as a multi-category incumbent rather than a generics specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mepha

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mepha Pharma